Omeprazole vs Lansoprazole: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Omeprazole irreversibly inhibits the H+/K+ ATPase proton pump as a racemic mixture, raising gastric pH above 4.0. CTD documents 183 gene interactions — the highest of any PPI — reflecting the racemic mixture's broad molecular reach across CYP enzymes, drug transporters, and inflammatory pathway genes. The R-enantiomer contributes to these off-target interactions without adding therapeutic acid suppression, creating a wider metabolic footprint than necessary for the clinical goal.
Omeprazole has only 35% oral bioavailability with a 0.75-hour half-life and 95% protein binding. The low bioavailability means variable acid suppression depending on CYP2C19 genetic status and food intake timing.
- ✓Lowest cost PPI — available OTC as generic, making it the most accessible acid suppressor globally
- ✓ChEMBL documents 395 RCTs — by far the most extensively studied PPI in clinical history
- ✓FAERS logs 122,780 reports providing unmatched real-world safety data
- ✓Available OTC without prescription for short-term self-management of heartburn
- ✗183 CTD gene interactions — the broadest molecular footprint of any PPI
- ✗Only 35% bioavailability creates variable acid suppression and unpredictable depletion patterns
- ✗CYP2C19 interaction reduces clopidogrel efficacy — FDA-issued black box interaction warning
- ✗Racemic mixture's R-enantiomer adds off-target effects without therapeutic benefit
Cost-conscious patients with mild-to-moderate GERD who aren't on CYP2C19-sensitive medications and need the most affordable acid suppression option.
Lansoprazole inhibits the same proton pump through irreversible covalent binding but with a narrower molecular profile than omeprazole. CTD documents 88 gene interactions — less than half of omeprazole's 183 — indicating fewer off-target metabolic effects. The acid suppression and six-nutrient depletion pattern are identical: raising gastric pH impairs iron conversion, calcium dissolution, B12 protein cleavage, and absorption of magnesium, zinc, and vitamin C.
Lansoprazole achieves 81% oral bioavailability — over 2x omeprazole's 35% — with a 1-hour half-life, reaching peak levels in 1.3 hours. Available in orally disintegrating tablet form.
- ✓81% bioavailability provides more consistent acid suppression than omeprazole's variable 35%
- ✓Fewer CTD gene interactions (88 vs 183) — narrower off-target profile than omeprazole
- ✓Orally disintegrating tablet available for patients with swallowing difficulties
- ✓ChEMBL documents 137 RCTs with proven efficacy across GERD, ulcers, and H. pylori eradication
- ✗FAERS logs 163,009 reports with 18.6% death-associated rate — higher than omeprazole's volume
- ✗Still has moderate CYP2C19 interaction potential — not recommended with clopidogrel
- ✗Higher cost than generic omeprazole OTC, though available as affordable generic
- ✗88 gene interactions still represent a substantial off-target profile, just less than omeprazole's
Patients who need more consistent acid suppression than omeprazole provides, especially those with swallowing difficulties who benefit from the orally disintegrating formulation.
Feature Comparison
| Feature | Omeprazole | Lansoprazole |
|---|---|---|
| Drug Class | PPI (racemic benzimidazole) | PPI (substituted benzimidazole) |
| Nutrients Depleted | 6 — Mg, Ca, Fe, B12, Zn, vitamin C | 6 — Mg, Ca, Fe, B12, Zn, vitamin C |
| Bioavailability | 35% | 81% (2.3x higher) |
| CTD Gene Interactions | 183 documented | 88 documented |
| FAERS Reports | 122,780 total | 163,009 total |
| Half-Life | 0.75 hours | 1.0 hours |
| Cost | Lowest (OTC generic) | Low (generic, slightly higher) |
| Special Formulations | Capsules, OTC tablets | Capsules, orally disintegrating tablets |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both PPIs deplete the same six nutrients through identical proton pump inhibition — your supplementation protocol doesn't change. The pharmacokinetic gap is substantial: lansoprazole's 81% bioavailability delivers more consistent acid suppression than omeprazole's variable 35%, and its 88 CTD gene interactions are less than half of omeprazole's 183, indicating a cleaner molecular profile. However, According to FAERS analysis, lansoprazole has 163,009 reports and an 18.6% death-associated rate versus omeprazole's 122,780, likely reflecting different prescribing populations. For cost-sensitive patients with mild symptoms, generic omeprazole OTC is the cheapest effective option. For patients needing reliable acid control or who can't swallow pills, lansoprazole's better bioavailability and orally disintegrating tablet give it practical advantages worth the modest cost premium.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 183 gene interactions for omeprazole; 88 for lansoprazole with different pathway distributions
- [2]ChEMBL bioactivity database: 395 RCTs for omeprazole; 137 RCTs for lansoprazole across GI indications
- [3]FAERS (FDA Adverse Event Reporting System): 122,780 omeprazole reports; 163,009 lansoprazole reports (18.6% death-associated)
- [4]PharmGKB pharmacogenomics database: CYP2C19 metabolizer annotations for both PPIs; clopidogrel interaction warnings
- [5]PubMed PMID 26462987 — Cheungpasitporn W et al. Proton pump inhibitors linked to hypomagnesemia. QJM. 2015;108(7):523-530
Check your medications
Check Free →